KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Short-term Investments (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Short-term Investments data on record, last reported at $215.8 million in Q4 2025.

  • For Q4 2025, Short-term Investments rose 31175.22% year-over-year to $215.8 million; the TTM value through Dec 2025 reached $215.8 million, up 31175.22%, while the annual FY2025 figure was $215.8 million, 31175.22% up from the prior year.
  • Short-term Investments reached $215.8 million in Q4 2025 per PACB's latest filing, down from $242.2 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $583.7 million in Q4 2021 and bottomed at $200000.0 in Q3 2021.
  • Average Short-term Investments over 5 years is $171.3 million, with a median of $763000.0 recorded in 2021.
  • Peak YoY movement for Short-term Investments: crashed 99.95% in 2022, then skyrocketed 150401.67% in 2023.
  • A 5-year view of Short-term Investments shows it stood at $583.7 million in 2021, then plummeted by 99.95% to $300000.0 in 2022, then surged by 150401.67% to $451.5 million in 2023, then tumbled by 99.85% to $690000.0 in 2024, then skyrocketed by 31175.22% to $215.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short-term Investments were $215.8 million in Q4 2025, $242.2 million in Q3 2025, and $259.9 million in Q2 2025.